B-HT 920 is a full agonist at both pre- and postsynaptic D-2 dopamine receptors

[1]  S. Hjorth,et al.  Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist SK&F 38393 , 2004, Psychopharmacology.

[2]  N. Andén,et al.  Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  R. Roth,et al.  Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors , 1976, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  N. Andén,et al.  Dopamine and noradrenaline receptor stimulation: Reversal of reserpine-induced suppression of motor activity , 2004, Psychopharmacologia.

[5]  K. Modigh.  Central and peripheral effects of 5-hydroxytryptophan on motor activity in mice , 2004, Psychopharmacologia.

[6]  J. Davis,et al.  Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in Vivo using an inhibitor of the aromatic amino acid decarboxylase , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  K. Bogeso,et al.  Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. , 1988, Pharmacology & toxicology.

[8]  O. Hornykiewicz,et al.  Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation. , 1988, European journal of pharmacology.

[9]  N. Andén,et al.  Increased motor activity following combined stimulation of B-HT 920-sensitive and D-1 dopamine receptors. , 1987, Acta physiologica Scandinavica.

[10]  N. Andén,et al.  Inhibitory role of D‐1 dopamine receptors for the jerks induced by B‐HT 920 in rats , 1987, The Journal of pharmacy and pharmacology.

[11]  O. Hornykiewicz,et al.  The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment. , 1986, European journal of pharmacology.

[12]  W. Lovenberg,et al.  Evidence for a specific effect of BHT 920, an azepine derivative, on tyrosine hydroxylase in the dopaminergic system of the rat. , 1986, European journal of pharmacology.

[13]  P. Mitchell,et al.  Dopamine autoreceptors and the effects of drugs on locomotion and dopamine synthesis , 1985, British journal of pharmacology.

[14]  N. Andén,et al.  Effects of B-HT 920 and B-HT 933 on dopamine and noradrenaline autoreceptors in the rat brain. , 2009, Acta pharmacologica et toxicologica.

[15]  P. Kissinger,et al.  DETERMINATION OF CATECHOLAMINES IN RAT BRAIN PARTS BY REVERSE‐PHASE ION‐PAIR LIQUID CHROMATOGRAPHY , 1978, Journal of neurochemistry.

[16]  T. Svensson,et al.  Thyroxine and brain catecholamines: increased transmitter synthesis and increased receptor sensitivity. , 1974, Brain research.

[17]  A. Carlsson,et al.  Evidence for a receptor‐mediated feedback control of striatal tyrosine hydroxylase activity , 1972, The Journal of pharmacy and pharmacology.

[18]  M. Goldstein,et al.  The inhibition of catecholamine biosynthesis by apomorphine , 1970, The Journal of pharmacy and pharmacology.